A month has gone by since the last earnings report for Penumbra (PEN) . Shares have added about 20% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Penumbra Q2 Earnings Miss, Gross Margin Contracts Penumbra ...

ALAMEDA, Calif., Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024. Event: Baird Global Healthcare Conference Date: Tuesday, September 10, 2024 Time: 9:05am ET/6:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on t ...

ALAMEDA, Calif., Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. Event: Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 2:15pm ET/11:15am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on ...

asikkk/iStock via Getty Images Penumbra (NYSE:PEN) is a leader in the field of medical technology, with both vascular and neurological devices making a big splash in the improvement of care. The stock has been volatile over the past few years, with a peak of $340 in late June 2023 making way to a low of $148 recently. Now the shares are intriguing at $191/share as excitement for the new Lightning Flash and Thunderbolt are continuing to help drive revenue growth. They are both computed assisted vacuum thromb ...

To Include $100 Million Accelerated Share Repurchase ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million, allowing Penumbra to repurchase its common stock from time to time at such prices as it deems appropriate through open market purchases, block transactions, privately negotiated transactions, including ...

ALAMEDA, Calif., Aug. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Growth Conference on Tuesday, August 13, 2024. Event: Canaccord Genuity Growth Conference Date: Tuesday, August 13, 2024 Time: 9:00am ET/6:00am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the co ...

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. The reported revenue represents a surprise of +0.28% over the Zacks Consensus Estimate of $298.58 million. With the consensus EPS estimate being $0.56, the EPS surprise was +14.29%. Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Stree ...

Penumbra, Inc. (NYSE:PEN) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Michael Sarcone - Jefferies Pito Chickering - Deutsche Bank Richard Newitter - Truist Securities Operator Good afternoon. My name is Aaron, and I will be your con ...

Penumbra (PEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this medical device maker would post earnings of $0.42 per share when it actually produced earnings of $0.41, delivering a surprise of -2.38%. Over the last four quarters, the co ...

Table of Contents Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Marketable investments classified within Level 2 of the fair value hierarchy are valued based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted p ...